Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The company expects sales of Orgovyx, Gemtesa and other products to expand in North America and sales milestone revenue from Orgovyx to be recorded, while also expecting higher research and development expenses to accelerate clinical development, the gain from the partial transfer of the Asian business recorded in the previous fiscal year, and the reversal of the temporary decrease in tax expenses recorded in the previous fiscal year.
Impairment loss of ¥2,073 million (fiscal year ended March 2026)
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥540,000 million（19.1% (vs. previous fiscal-year results)） |
| Operating profit | Not disclosed → ¥90,000 million（-16.2% (vs. previous fiscal-year results)） |
| Profit attributable to owners of the parent | Not disclosed → ¥77,000 million（-27.9% (vs. previous fiscal-year results)） |
| Net income per share | Not disclosed → 172.89 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Fiscal year ended March 2026 results: revenue of ¥453,294 million, operating profit of ¥107,338 million, profit for the year attributable to owners of the parent of ¥106,865 million, and basic earnings per share of ¥268.99 |
| Reason for the revision | The company expects sales of Orgovyx, Gemtesa and other products to expand in North America and sales milestone revenue from Orgovyx to be recorded, while also expecting higher research and development expenses to accelerate clinical development, the gain from the partial transfer of the Asian business recorded in the previous fiscal year, and the reversal of the temporary decrease in tax expenses recorded in the previous fiscal year. |
| Details and amount of extraordinary loss | Impairment loss of ¥2,073 million (fiscal year ended March 2026) |
| Dividend forecast revision | The interim and year-end dividends for the fiscal year ending March 2027 have not been determined. The year-end dividend for the fiscal year ended March 2026 will be nil, as initially forecast. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased in the fiscal year ended March 2026, mainly because sales of Orgovyx and Gemtesa expanded in North America and sales milestone revenue from Orgovyx was recognized. For the fiscal year ending March 2027, the company expects revenue to increase on the expansion of sales of its North American products, while forecasting lower profit due to higher research and development expenses associated with accelerated clinical development, the gain on the partial transfer of the Asian business recorded in the previous fiscal year, and the reversal of the temporary decrease in tax expenses recorded in the previous fiscal year.